Metaglez Forte Tablet contains a combination of Glipizide 5mg and Metformin 500mg, utilized in the management of type 2 diabetes mellitus. Glipizide, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. This dual-action formulation is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal blood glucose levels. Metaglez Forte is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of blood glucose levels, renal function, and periodic assessment of liver enzymes is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Metaglez Forte should be used under medical supervision to minimize risks and optimize glycemic control in patients with type 2 diabetes.